Overview of Uroctal

Quick Facts

Property	Description
Active ingredient	Norfloxacin [INN]
Form	Film-coated tablet
Pharmacological class	Fluoroquinolone antibacterial agent
Common use	Systemic bacterial infection treatment
Origin	Synthetic

What Type of Medicine is Uroctal (Norfloxacin)?

Uroctal is a pharmaceutical preparation that contains the active ingredient Norfloxacin, and is formally classified as a Fluoroquinolone antibacterial agent. This drug is a completely synthetic compound, belonging to a class of antimicrobials clinically recognized for their broad-spectrum activity against a notable range of bacterial pathogens. The development of this compound included the strategic addition of a fluorine atom, which distinguishes it from older quinolone agents and enhances its therapeutic efficacy. Norfloxacin is categorized as a first-generation fluoroquinolone typically used to combat bacterial infections systemically.

Composition, Mechanism, and General Therapeutic Purpose

The core composition of Uroctal is the active substance Norfloxacin [INN] combined with solid pharmaceutical excipients, characteristically delivered as a film-coated tablet intended for oral administration. The film-coating is a specific pharmaceutical preparation that facilitates reliable delivery of the Norfloxacin for systemic absorption. The general therapeutic mission of this agent is to exert a bactericidal effect. This action is achieved by Norfloxacin specifically inhibiting two bacterial enzymes, DNA gyrase and Topoisomerase IV, which are critical for the replication, transcription, and repair of bacterial DNA. By blocking these essential processes, the drug prevents the growth and division of susceptible bacteria, serving to halt the progression of bacterial illness.

Regulatory References

NIH LiverTox

What side effects are possible with Uroctal?

Official Safety Profile and Adverse Reactions

Regulatory documents classify the potential side effects of Norfloxacin, a fluoroquinolone antibacterial, by how frequently they may appear across different physiological systems. These classifications guide the official understanding of the medicine’s risk profile, based strictly on government-approved labeling.

Frequency Classification of Adverse Effects

Classification	Examples of Documented Adverse Reactions
Common (1/100 to <1/10)	Nausea
Uncommon (1/1,000 to <1/100)	Headache, dizziness, sleep disorders, depression, rash, and various gastrointestinal disturbances like flatulence, diarrhoea, or constipation.
Rare (1/10,000 to <1/1,000)	Tendinitis, tendon rupture, paraesthesia, anaphylactoid reactions.

Serious Adverse Reactions

Official prescribing information highlights specific, clinically significant adverse reactions. Fluoroquinolones, including Norfloxacin, are associated with an increased risk of tendinitis and tendon rupture. The label also notes the potential for peripheral neuropathy, which may occur rapidly after treatment initiation and can be potentially permanent. Other serious reactions documented include Clostridium difficile-associated diarrhea (CDAD), seizures, and a rare potential for QT prolongation.

Population-Specific Safety Considerations

The regulatory profile includes specific notes for certain patient groups. The risk of tendon rupture is noted as significantly increased in older adults. For patients with severe renal impairment, the label states that monitoring plasma concentrations is required. Furthermore, the official label specifies safety limitations, including contraindication in individuals with a history of hypersensitivity to any fluoroquinolone and the risk of phototoxicity reactions upon exposure to sunlight.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documentation establishes that if an overdose of Uroctal (Norfloxacin) is suspected, it is mandatory to seek emergency medical attention immediately. This urgency is based on the potential for severe, life-threatening outcomes detailed in the prescribing information.

Documented Overdose Manifestations

Regulatory labeling identifies a spectrum of clinical manifestations associated with acute overexposure. These potential signs include gastrointestinal disturbances such as vomiting, diarrhoea, and gastrointestinal haemorrhage. Neurological effects such as dizziness, tinnitus, and convulsions are also documented as part of the official overdose profile.

Potential Severe Outcomes

In the event of significant poisoning, an overdose carries the formal risk of severe organ system damage. Regulatory authorities note the potential for acute renal failure and liver damage as serious complications that may arise.

Officially Described Management and Observation

Treatment for Norfloxacin overdosage is strictly defined as symptomatic and supportive. Regulatory directives require that the patient be carefully observed and monitored. While no specific antidote is reported, the required initial procedure for acute overdosage involves gastric decontamination, such as inducing vomiting or gastric lavage. The use of activated charcoal may also be considered. Additionally, adequate hydration must be maintained to mitigate the possible development of crystalluria.

Therapeutic Uses of Uroctal

Uroctal (Norfloxacin) is used for managing specific bacterial infections, supporting the patient during episodes of heightened discomfort.

Norfloxacin is commonly used across conditions presenting with systemic or localized discomfort. This involves conditions presenting with systemic or localized discomfort, such as infections of the urinary tract (cystitis, urethritis, prostatitis), and specific gastrointestinal conditions where symptoms may intensify temporarily (traveler's diarrhea).

The medication is applied in addressing symptoms related to inflammatory or irritative states, which contributes to easing symptom clusters that interfere with daily functioning. These manifestations include symptoms related to physical discomfort such as painful or burning urination (dysuria), frequent urges to pass urine, and inflammatory discomfort.

“This approach may assist with maintaining functional stability during episodes where patients experience symptoms related to inflammatory or irritative states.”

Its use is considered relevant in the prophylactic setting when symptoms are associated with acute or disruptive episodes, assisting with maintaining functional stability in certain high-risk patients.

Quick Fact: Relief for Urinary Distress and Functional Strain

Property	Description
Primary Domain	Genitourinary Tract Infections
Symptom Focus	Dysuria, Urinary Frequency, Inflammatory Discomfort
Core Benefit	Contributes to easing the overall symptom load

Regulatory References

NIH LiverTox overview

Eligibility and Restrictions for Use

Eligibility: Who Can and Cannot Use Uroctal?

Uroctal (Norfloxacin) is generally established for use in the general adult population (18 years and older). However, regulatory authorities define strict eligibility boundaries based on absolute prohibitions and restrictions.

Absolute Prohibitions (Contraindications)

The medicine is contraindicated and must not be used by individuals with a known history of hypersensitivity to Norfloxacin or any other quinolone. Use is also strictly prohibited in patients with a history of tendinitis or tendon rupture related to previous fluoroquinolone administration. Uroctal must not be used in patients with a history of Myasthenia Gravis.

Age and Reproductive Status

Eligibility is strictly limited by age: the medicine is contraindicated or not recommended for children and growing adolescents (under 18 years of age), as safety and efficacy have not been established. Furthermore, use is formally contraindicated during pregnancy and breastfeeding.

Conditional or Restricted Use

Conditional use is required for several populations. Patients with severe renal impairment ( CrCl le 30 mL/min) or certain Central Nervous System (CNS) disorders (e.g., epilepsy, seizure risk) have restricted eligibility for standard use. Older Adults may be treated, but regulatory labeling notes this population has an increased risk of tendon damage, requiring special caution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The co-administration of Uroctal with products containing polyvalent cations, such as antacids (magnesium/aluminum), iron, zinc supplements, multivitamins, sucralfate, or certain buffered Didanosine forms, will significantly reduce Norfloxacin absorption. To prevent this reduction in exposure, regulatory labels mandate that these products must not be taken within two hours of Norfloxacin administration.

Norfloxacin is documented as an inhibitor of the CYP1A2 metabolic enzyme. This pharmacokinetic interaction reduces the clearance of co-administered CYP1A2 substrates, leading to elevated plasma concentrations. Specific medicines affected include Theophylline, Tizanidine, and Caffeine.

Official prescribing information lists several additive risks. Co-administration with Class IA and Class III antiarrhythmics should be avoided due to the increased risk of QTc interval prolongation. An enhanced risk of CNS stimulation and seizures exists with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Furthermore, elevated serum levels of Cyclosporine and enhanced anticoagulant effects of Warfarin have been formally reported.

The regulatory profile also notes that the combination with Nitrofurantoin is not recommended due to potential antibacterial antagonism.

Mechanism of Action

Dual Inhibition of Bacterial DNA Integrity

Uroctal (Norfloxacin) operates by a highly targeted mechanism focused on disrupting the core processes of bacterial DNA maintenance, classifying its action as bactericidal. The drug acts as a Topoisomerase poison by binding to and simultaneously inhibiting two critical bacterial enzymes: DNA Gyrase (Topoisomerase II) and Topoisomerase IV. By stabilizing the enzyme-DNA cleavage complex, the drug converts these enzymes into agents that actively induce lethal, double-stranded breaks in the pathogen's DNA.

The Lethal Mechanistic Cascade

This molecular interaction rapidly halts the bacterial DNA replication fork and prevents the final segregation of daughter chromosomes. This dual blockade overwhelms the bacteria's repair mechanisms, causing irreversible genetic damage that ultimately results in the swift, controlled cell death of the pathogen, leading to the suppression of pathogen proliferation throughout the system.

Constraints on Pathogen Response

The mechanism's efficacy is constrained by factors internal to the bacterium, specifically the development of target-site mutations (reducing drug affinity to the enzymes) and the increased expression of efflux pumps that actively expel Norfloxacin from the cell, thus reducing the magnitude of the resulting bactericidal activity.

Dosage and Administration Information

How to Use Uroctal (Norfloxacin)

This section summarizes the instructions for using Uroctal. Norfloxacin is administered orally, meaning the tablet must be swallowed by mouth.

Official Administration Protocol

The standard dosage for many indications is 400 mg taken every 12 hours (twice daily). Treatment duration varies and must be followed completely as prescribed, even if symptoms improve. For adults with significantly reduced renal function (creatinine clearance 30 mL/min/1.73 m^2), the required dose is reduced, typically to 400 mg once daily.

Procedural Instruction	Requirement
Timing	Must be taken at least 1 hour before or 2 hours after a meal, milk, or any other dairy products.
Method	Swallow the tablet whole with a full glass of water. Do not crush or chew.
Co-administration	Avoid taking the dose within 2 hours of antacids, sucralfate, iron supplements, or multivitamins containing iron or zinc.
Hydration	Patients must drink plenty of fluids daily to maintain proper hydration and ensure adequate urinary output.

Management of Missed Doses

If a scheduled dose is missed, take the dose as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose must be skipped. Patients should not take two doses simultaneously to make up for a missed dose.

Recent Clinical Evidence

Research evidence / Overview of studies for Uroctal

This overview describes the types of clinical research that examined Uroctal (Norfloxacin) in different settings, focusing on the conditions it was studied for and the nature of the research findings, without providing clinical advice or treatment recommendations.

Evidence for Use in Acute Lower Urinary Tract Infections

The research was studied for conditions characterized by episodic or acute changes, specifically uncomplicated infections of the lower urinary tract, such as cystitis. This area was evaluated in short-term, randomized controlled trials (RCTs) and other comparative studies.

Research examined how symptoms evolved in the observed populations, with studies focusing on outcomes related to physical discomfort like painful urination. The research also monitored the rate of bacteriological eradication, which measures the rates of bacteriological outcomes. Findings describe patterns observed in the studies over the short course of treatment, where patterns of symptom evolution and rates of bacteriological outcomes was monitored in the studied populations.

However, the applicability of evidence may be influenced by the type of infection. Regulatory bodies describe that the evidence is limited for some complicated kidney infections (pyelonephritis), indicating that research for different parts of the urinary system is not fully established or consistent across all infection types.

Evidence for Prophylactic and Preventative Uses

Research has explored the structure of evidence for Uroctal in conditions characterized by fluctuating or episodic manifestations, particularly in two distinct settings:

Prophylaxis for Recurrent Urinary Tract Infection (RUTI)

Studies examined the use of Norfloxacin over long periods was studied for recurrent conditions. Research has explored its structure of evidence in trials that examined patterns related to the frequency of UTI recurrence compared to other approaches. Findings indicate that during the period the study medication was evaluated in the observed populations, there was observed in some studies a pattern of lower recurrence rates compared to the placebo group.

Prophylaxis for Spontaneous Bacterial Peritonitis (SBP)

In patients with advanced liver conditions, Norfloxacin was studied for approaches related to a complication known as SBP. The evidence base here includes systematic reviews and meta-analyses. Research monitored the incidence rate of SBP and also examined patient survival (all-cause mortality) over defined time intervals. Data show patterns related to a consistently lower rate of SBP incidence in the studied groups. However, when research examined survival, findings were mixed, and the certainty remains low regarding whether this preventative use was associated with long-term patterns in mortality.

Evidence for Managing Acute Gastrointestinal Infections

The evidence base for the use of Uroctal in acute gastrointestinal issues was evaluated in short-term, double-blind, placebo-controlled RCTs. This approach was studied for both treating active acute diarrhea and for prevention (prophylaxis) in travelers.

Studies explored outcomes related to systemic or functional imbalance, specifically monitoring the duration of diarrhea symptoms and the rate of full clinical recovery. Findings describe patterns where duration was observed to be shorter in the treated groups compared to placebo. For prophylaxis, data show patterns related to a lower incidence of developing diarrhea in groups receiving Norfloxacin during travel.

Research in Selected Clinical Situations and Populations

Research has explored the structure of evidence for Uroctal in situations that require a longer treatment course, such as Chronic Bacterial Prostatitis in adult males.

Study Focus: The trials in this area were conducted during periods of increased symptom activity and monitored outcomes linked to inflammatory or irritative states, focusing on the eradication of the pathogen and symptom resolution over medium-term courses (e.g., four to six weeks).
Limitations: For this condition, evidence quality varies across studies, with many trials having sample sizes were modest or being conducted without a comparative control group. As a result, data for certain groups remain insufficient, and evidence is limited for fully understanding the long-term changes in this population.

What Research Gaps and Uncertainties Remain

The scientific record describes areas where research is limited, inconsistent, or where data are still emerging regarding evolving resistance patterns.

Data Applicability: The patterns observed in SBP prophylaxis was associated with questions about the applicability of findings, and further studies are ongoing to understand this phenomenon.
Limited Subgroups: Research has explored whether findings were lower in studies including patients with increased ascites protein or exceedingly high serum bilirubin levels.
Methodological Limitations: Methodological issues, such as a limited number of evaluable patients and older study designs, restrict the depth of the evidence for certain indications, such as Chronic Bacterial Prostatitis.
Antimicrobial Resistance: Across all indications, the rise of antimicrobial resistance data are still emerging, and it was observed in some studies that resistance can emerge after prolonged exposure.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Uroctal (FAQ)

Q: Is Uroctal a prescription-only drug?

According to the official classification by government agencies, Uroctal (Norfloxacin) is a prescription-only medicine (Rx-only).

This classification means the drug is not available for purchase over the counter and requires authorization from a licensed healthcare professional to be dispensed.

Q: Is Uroctal available as a generic version?

Regulatory documents have determined that generic versions of Norfloxacin, the active ingredient in Uroctal, may be approved.

These generic versions are subject to meeting all necessary legal and regulatory requirements for quality, safety, and regulatory equivalence.

Q: Is Uroctal considered a cure for the condition it treats?

Official documents describe the drug's purpose as the treatment and prevention of infections, and not specifically as a 'cure.'

It works by eradicating susceptible bacteria and halting the progression of the bacterial illness. Regulatory documents emphasize that the full course of treatment is generally required to achieve the therapeutic goals described.

Q: Is Uroctal a narcotic or habit-forming medicine?

Uroctal is formally classified as a Fluoroquinolone antibacterial agent.

This class of medicine is not categorized as a narcotic or a controlled substance by regulatory authorities. As a result, it is not classified by regulatory bodies as a medication with known habit-forming potential.

Q: What is the typical shelf life of an unopened package of Uroctal?

Regulatory documents that detail storage conditions specify that Norfloxacin tablets should be stored below 30 C (86 F).

These documents may also state a typical shelf life of up to 18 months, depending on the specific product formulation and packaging.

Q: Is Uroctal linked to complications with liver function?

Official regulatory information notes that changes in liver function tests have been documented in association with this medicine. These changes can sometimes indicate serious liver problems.

Official documents recommend consulting with a healthcare professional if signs suggestive of a liver issue are observed while taking this medicine.

Q: Are there any restrictions on driving or operating machinery while taking Uroctal?

Official labeling advises against engaging in activities that require full mental alertness and coordination, such as driving or operating machinery.

This warning is in place because Uroctal has the potential to cause side effects like dizziness or lightheadedness. The official warning indicates that patients should not engage in these activities until the effects of the medicine on the individual are understood.

Q: Should I inform my doctor if I am taking other prescription medications with Uroctal?

Patient counseling guidelines consistently recommend informing your healthcare provider about everything you are currently using.

This includes all prescription and non-prescription medicines, vitamins, herbal products, and any other supplements. This information assists the healthcare provider in evaluating the risks associated with potential drug interactions.

Q: Is it safe to consume alcohol in moderation while using Uroctal?

Official regulatory materials do not list a specific pharmacological interaction between Uroctal (Norfloxacin) and alcohol (ethanol).

However, since this medicine can cause side effects like dizziness, it is generally recommended to be cautious and to consult with a healthcare professional regarding individual alcohol consumption while using Uroctal.

How should Uroctal be stored and disposed of?

Storage and Disposal Requirements for Uroctal (Norfloxacin)

Official Storage Instructions

Uroctal tablets must be stored at a controlled room temperature, specifically maintained between 15 C and 30 C (59 F and 86 F). The medication must be kept away from excessive heat, moisture, and direct light. It is a mandatory requirement to keep the product from freezing and to ensure the container remains tightly closed. For safety, Uroctal must always be stored out of the sight and reach of children.

Disposal Requirements

To prevent environmental contamination, unused or expired Uroctal tablets must never be discarded in household trash or poured down a sink or drain. Regulatory guidelines recommend disposing of outdated medicine through a formal pharmacy take back program or another authorized pharmaceutical waste collection service.

Uroctal